Plasma proteome profiling using tandem mass tag labeling technology reveals potential biomarkers for Parkinson's Disease: a preliminary study

2021 ◽  
pp. 2100010
Author(s):  
Yuan Zhao ◽  
Yidan Zhang ◽  
Jian Zhang ◽  
Guofeng Yang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Tandem Mass ◽  
Plasma Proteome ◽  
Proteome Profiling ◽  
Tandem Mass Tag ◽  
Preliminary Study ◽  
Potential Biomarkers ◽  
Mass Tag

scholarly journals Tandem Mass Tag-Based Serum Proteome Profiling for Biomarker Discovery in Young Duchenne Muscular Dystrophy Boys

ACS Omega ◽  
2020 ◽  
Vol 5 (41) ◽  
pp. 26504-26517
Author(s):  
Tchilabalo D. Alayi ◽  
Shefa M. Tawalbeh ◽  
Michael Ogundele ◽  
Holly R. Smith ◽  
Alison M. Samsel ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Biomarker Discovery ◽  
Tandem Mass ◽  
Proteome Profiling ◽  
Serum Proteome ◽  
Tandem Mass Tag ◽  
Mass Tag

scholarly journals Tandem Mass Tag-Based Proteomic Analysis of Potential Biomarkers for Hepatocellular Carcinoma Differentiation

2021 ◽  
Vol Volume 14 ◽  
pp. 1007-1020
Author(s):  
Wei Wang ◽  
Qiang Li ◽  
Ge Huang ◽  
Bing-yao Lin ◽  
Dong-Zi Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Proteomic Analysis ◽  
Tandem Mass ◽  
Tandem Mass Tag ◽  
Potential Biomarkers ◽  
Mass Tag

1H MR Spectroscopy in Parkinson's Disease and Progressive Supranuclear Palsy: Preliminary Study

1996 ◽  
Vol 34 (6) ◽  
pp. 711
Author(s):  
Kee Hyun Chang ◽  
Beom Seok Jeon ◽  
In Chan Song ◽  
Dong Sung Kim ◽  
Kwan Hong Min ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Progressive Supranuclear Palsy ◽  
Mr Spectroscopy ◽  
1H Mr Spectroscopy ◽  
Preliminary Study

Identification of novel autoantibodies in ascites of relapsed paclitaxel-resistant gastric cancer with peritoneal metastasis using immunome protein microarrays and proteomics

2021 ◽  
pp. 1-10
Author(s):  
Zhongyin Yang ◽  
Chao Yan ◽  
Wentao Liu ◽  
Wei Xu ◽  
Chen Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Effective Treatment ◽  
Peritoneal Metastasis ◽  
Quantitative Proteomics ◽  
Poor Prognosis ◽  
Protein Microarrays ◽  
Tandem Mass ◽  
Tandem Mass Tag ◽  
Resistant Group ◽  
Potential Biomarkers

BACKGROUND: Gastric cancer (GC) patients with peritoneal metastasis usually have extremely poor prognosis. Intraperitoneal infusion of paclitaxel (PTX) provides an effective treatment, but relapse and PTX-resistance are unavoidable disadvantages, and it is difficult to monitor the occurrence of PTX-resistance. OBJECTIVE: The aim of this study was to explore novel autoantibodies in the ascites of individuals with relapsed PTX-resistant GC with peritoneal metastasis. METHODS: Ascites samples were collected before PTX infusion and after the relapse in 3 GC patients. To determine the expression of significantly changed proteins, we performed autoantibody profiling with immunome protein microarrays and tandem mass tag (TMT) quantitative proteomics, and then, the overlapping proteins were selected. RESULTS: Thirty-eight autoantibodies that were differentially expressed between the ascites in the untreated group and relapsed PTX-resistant group were identified. For confirmation of the results, TMT quantitative proteomics was performed, and 842 dysregulated proteins were identified. Four proteins, TPM3, EFHD2, KRT19 and vimentin, overlapped between these two assays. CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients. These autoantibodies may be used as potential biomarkers to monitor the occurrence of PTX-resistance.

Sign in / Sign up

Export Citation Format

Share Document